Publications in collaboration with researchers from Clínica Universitaria de Navarra (107)

2024

  1. Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study

    Clinical Genitourinary Cancer, Vol. 22, Núm. 5

  2. Intratumoral NK cell delivery combined with neutralization of the NKG2A pathway as treatment for solid cancer

    Genes and Immunity

  3. Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040

    Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548

  4. Spatially resolved tissue imaging to analyze the tumor immune microenvironment: beyond cell-type densities

    Journal for immunotherapy of cancer, Vol. 12, Núm. 5

  5. Tumor slice culture system for ex vivo immunotherapy studies

    Methods in Cell Biology (Academic Press Inc.)

2023

  1. Longitudinal analysis of DC subsets in patients with ovarian cancer: Implications for immunotherapy

    Frontiers in Immunology, Vol. 14

  2. Reply to letter to the editor “Bureaucracy or Streamlining the Rules in “Good Clinical Practice (GCP)” - Has Equipoise Occurred?” by H. K. Kotikonda, V. G. Jonnalagadda and S. R. Venna

    Annals of Oncology

  3. Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials

    Annals of Oncology, Vol. 34, Núm. 1, pp. 70-77

  4. The Lymphatic Endothelium in the Context of Radioimmuno-Oncology

    Cancers, Vol. 15, Núm. 1

2022

  1. Cancer vaccines: the next immunotherapy frontier

    Nature Cancer, Vol. 3, Núm. 8, pp. 911-926

  2. Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary Group

    Clinical Genitourinary Cancer, Vol. 20, Núm. 4, pp. 388.e1-388.e10

  3. Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers

    ESMO Open, Vol. 7, Núm. 2

  4. Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer

    Cancer Discovery, Vol. 12, Núm. 5, pp. 1356-1377

2021

  1. An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad antitumor activity in humanized murine cancer models without toxicity

    Clinical Cancer Research, Vol. 27, Núm. 11, pp. 3167-3177

  2. Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, Núm. 26

  3. Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies

    Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 882-891

  4. CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function

    Cancer Immunology Research, Vol. 9, Núm. 12, pp. 1476-1490

  5. DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type i conventional dendritic cells

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 5

  6. IL8, neutrophils, and NETs in a collusion against cancer immunity and immunotherapy

    Clinical Cancer Research, Vol. 27, Núm. 9, pp. 2383-2393

  7. Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma

    European Urology Focus, Vol. 7, Núm. 5, pp. 1084-1091